文献速递血管炎其他结缔组织病

抗中性粒细胞胞质抗体相关血管炎中的间质性肺病:欧洲多中心研究

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A European Multicenter Study.
PubMed 文献 · Arthritis Rheumatol · 2026-03-13

该欧洲多中心回顾性研究纳入162例AAV-ILD或ANCA-ILD患者,其中MPO-ANCA阳性占85%。基线UIP模式最常见(57%),约半数纤维化分级>10%。UIP和NSIP模式年FVC%下降更明显,利妥昔单抗与12个月FVC%改善相关(+6.02%,P=0.07)。中位随访4.2年,48%死亡。

要点

  • 基线纤维化程度高、UIP模式及低FVC%与更差结局相关。
  • 利妥昔单抗可能与12个月FVC%改善相关(+6.02%,P=0.07)。
  • 呼吸衰竭与纤维化分级4级(HR 4.7)及基线FVC%相关。

核心结论

  • 基线纤维化程度更高、UIP模式及更低FVC%与更差结局相关。
  • 免疫抑制剂如利妥昔单抗可能有助于保护肺功能。
  • 强调对AAV或ANCA相关ILD需早期识别和个体化治疗。

研究设计与样本

  • 欧洲多中心回顾性研究,纳入162例AAV-ILD或ANCA-ILD患者。
  • 基线及后续胸部CT由中心统一复核。
  • 主要结局包括FVC%下降、呼吸衰竭和死亡。

主要发现

  • 162例中MPO-ANCA阳性85%,AAV-ILD 123例(76%),ANCA-ILD 39例(24%)。
  • 基线UIP为最常见影像模式(57%),半数影像纤维化分级>10%。
  • 肾脏受累占73%,最常见为Berden局灶型。
  • UIP年FVC%下降-1.99%,NSIP -3.76%(P=0.35),其他模式+0.36%。
  • 影像学进展约50%,多见于较年轻且纤维化程度更高的患者。

关键数值与推荐

  • 调整混合效应模型显示利妥昔单抗与12个月FVC%平均改善+6.02%相关(P=0.07)。
  • 呼吸衰竭(19%)与纤维化分级4级(HR 4.7,P=0.029)及基线FVC%(HR 0.95,P=0.002)相关。
  • 中位随访4.2年,48%死亡;年龄(HR 1.08,P=0.04)和基线FVC%(HR 0.97,P=0.05)为死亡独立预测因素。

临床怎么用

  • 对AAV或ANCA阳性患者应关注ILD的早期识别与评估。
  • 基线纤维化程度、UIP模式和FVC%可用于风险分层。
  • 利妥昔单抗可能作为保护肺功能的治疗选择,但证据尚待进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV-ILD) or as an isolated entity with positive ANCA (ANCA-ILD). However, data on the epidemiology and outcomes of these conditions remain limited. METHODS: A European multicenter retrospective study encompassed patients with AAV-ILD or ANCA-ILD. Baseline and subsequent chest computed tomography studies were centrally reviewed. Primary outcomes included forced vital capacity % (FVC%) decline, respiratory failure, and mortality. RESULTS: Of 162 patients (myeloperoxidase [MPO]-ANCA 85%), 123 (76%) had AAV-ILD and 39 (24%) ANCA-ILD. At baseline, usual interstitial pneumonia (UIP) was the most frequent radiologic pattern (57%), whereas half had a radiologic fibrosis grade >10%. Kidney involvement was present in 73%, most commonly Berden focal class. UIP and nonspecific interstitial pneumonia (NSIP) patterns showed greater annual FVC% decline than other patterns (UIP -1.99%, NSIP -3.76% [P = 0.35], others +0.36%). An adjusted mixed-effects model indicated that rituximab was associated with mean FVC% improvement at 12 months (+6.02%; P = 0.07). Radiologic progression occurred in ~50%, mainly in younger patients with a higher fibrosis severity grade. Respiratory failure (19%) was associated with fibrosis severity (grade 4 hazard ratio [HR] 4.7, P = 0.029) and baseline FVC% (HR 0.95, P = 0.002). Over a median 4.2-year follow-up, 48% died. Age (HR 1.08, P = 0.04) and baseline FVC% (HR 0.97, P = 0.05) were independent predictors of mortality. CONCLUSION: At baseline, higher fibrosis severity, UIP, and lower FVC% were associated with worse outcomes. Immunosuppressives, such as rituximab, may help preserve lung function. The need for early identification and individualized treatment in ILD associated with AAV or ANCA is underscored.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chalkia A, Kotnik M, Sadler TJ, et al. Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A European Multicenter Study. Arthritis Rheumatol. 2026. PMID: 41656587. doi:10.1002/art.70078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。